Smartwatch-guided exercise to prevent muscle loss during GLP-1 treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional program provides adults who recently started or plan to start GLP-1 receptor agonist therapy with a smartwatch that measures activity and body composition and delivers exercise reminders alongside general exercise guidance. Participants use the device during early treatment with liraglutide, semaglutide, tirzepatide, or retatrutide while investigators monitor changes in muscle mass and strength. Key inclusion criteria include age ≥18 and BMI ≥25 kg/m2, and exclusions include pregnancy, implanted pacemaker, or inability to participate in regular exercise. The study is conducted at the Diabetes Research Center at Massachusetts General Hospital in collaboration with Samsung.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Age ≥ 18 years old at time of signing informed consent
2. Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment

   a. Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment
3. Able to provide informed consent

Exclusion Criteria

1. Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months
2. BMI \<25 kg/m2 at the time of screening
3. Unable to participate in a regular physical exercise program
4. Implanted pacemaker
5. Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study

Where it's running

• Diabetes Research Center
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Melissa Putman, MD — Massachusetts General Hospital
• Study coordinator: Ben O Brenner, BS
• Email: bbrenner1@mgb.org
• Phone: 617-726-1729

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Exercise Self-Efficacy, Body Composition, and Activity in Men with Low Testosterone

  This study tests how confident men on testosterone therapy are at staying active and whether that confidence links body fat and lean mass with how much they exercise.

  Recruiting at 2 sites Hacettepe University · Bingoel and 1 other locations · NCT07924514

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.